Compound dossier · evidence, sources, and live market
Retatrutide
GLP-1 / triple agonist Moderate evidence 3 cited studies 30 live vendors
Retatrutide is a synthetic triple agonist peptide researched for its simultaneous activation of GLP-1, GIP, and glucagon receptors, studied in metabolic and energy homeostasis models. This price-comparison index tracks vendor listings for laboratory-use-only peptide material.
Evidence brief
Retatrutide is an experimental agonist of the GIP, GLP-1, and glucagon receptors that has been studied in early-phase human trials for obesity and related metabolic conditions.
first-party prices captured 37m ago
Compare by exact vialThe small sealed glass container a compound ships in. size: 5mg (4 vendors)10mg (24 vendors)15mg (6 vendors)20mg (16 vendors)24mg (3 vendors)30mg (22 vendors)40mg (6 vendors)50mg (5 vendors)60mg (10 vendors)
Investigational — in phase 3 trials (Eli Lilly); not approved by any regulator.Research use only — not medical advice.
These figures are what pepmg still publishes about price: the floor, the middle, the spread and how many sources we track, computed from listings we captured first-party and refreshed on the same schedule as always. We no longer publish the individual listings or the sellers behind them.
Computed from 106 in-stock listings across 30 sources we captured first-party, with bulk vials, blends and statistical outliers excluded so the figures compare like with like. The spread is the highest tracked price divided by the lowest — how much the same milligram varies depending on where you look. The chart is the daily minimum; days we did not capture are left out rather than filled in.
- Are research peptides safe? What the evidence does and doesn't show Limited evidence
"Are peptides safe?" has no single answer. The compounds sold as research peptides sit at very different points on the evidence scale, from large randomized human trials for a few to animal-only data for many.
Read the full review → - What the research says about retatrutide Moderate evidence
Retatrutide is an experimental agonist of the GIP, GLP-1, and glucagon receptors that has been studied in early-phase human trials for obesity and related metabolic conditions.
Read the full review →
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial PubMed ↗
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the…
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial PubMed ↗
Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8…
- Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials PubMed ↗
To assess the effects of once-weekly subcutaneous retatrutide on weight and metabolic markers and the occurrence of side effects in patients with overweight, obesity and/or type 2 diabetes (T2D). PubMed, Embase, Cochrane Library, and…
A few representative studies, each summarized on this site with the PubMed record linked beside it — not an endorsement or a claim that any result applies to human use. Read them and judge for yourself. Everything here is research use only.
▸ Why compare $/mg for Retatrutide?
Vendor prices per milligram vary due to differences in synthesis scale, purity guarantees, and third-party testing costs. Comparing prices helps researchers identify cost-effective sources that still meet their quality benchmarks for controlled studies.
▸ Reading the COA
For retatrutide, verify peptide identity via mass spectrometry and purity above 98% via HPLC. Check for common adulterants like residual solvents or truncated sequences, and confirm the reported mass matches the theoretical mass to rule out under-filling.
▸ FAQ
▸ Same cluster
| Tirzepatide | $1.35/mg | vs Retatrutide → |
| Semaglutide | $1.22/mg | vs Retatrutide → |
| Cagrilintide | $4.60/mg | vs Retatrutide → |
| AOD-9604 | $4.00/mg | vs Retatrutide → |
| HGH Frag 176-191 | $5.73/mg | vs Retatrutide → |
| 5-Amino-1MQ | $0.80/mg | vs Retatrutide → |
| Survodutide | $7.39/mg | vs Retatrutide → |
| Mazdutide | $5.72/mg | vs Retatrutide → |
| Teduglutide | $2.37/mg | |
| Orforglipron | $21.50/mg | vs Retatrutide → |
| Tesofensine | $159.98/mg | vs Retatrutide → |
| SLU-PP-332 | $3.33/mg | vs Retatrutide → |
| BAM15 | $1.96/mg | vs Retatrutide → |
| AICAR | $0.63/mg | vs Retatrutide → |
| Adipotide | $7.60/mg | vs Retatrutide → |
| L-Carnitine | $9.90/mg |